Wednesday, August 30, 2006

Ranbaxy wins LIPITOR case in Norway

An Oslo city court found that Ranbaxy's generic form of the drug LIPITOR, whose chemical name is atorvastatin, was not infringing two of Pfizer's Norwegian patents. [Reuters, August 29, 2006]

Relevant to the patent quality debate, one notes that different countries can have different rules on patents, and reach different results. Comparing patent grant rates from different countries can be perilous.

Separately, the Jerusalem Post reported that Teva Pharmaceutical Industries Ltd. (the world's largest generic-drug maker) said it will continue to sell a version of Purdue Pharma Ltd.'s OxyContin painkiller for an undisclosed period after settling a lawsuit.

The agreement will end a case in federal court in the southern district of New York [SD NY] and calls for Teva to halt sales at an unspecified date.

The report noted that "The accord requires approval of the Federal Trade Commission, the Justice Department and the court, Petah Tikva-based Teva said Tuesday" (Aug. 29).

A reminder required by Apotex and Plavix?

The report also noted: Last month, Purdue and Endo Pharmaceutical Holdings Inc. reached a settlement in an OxyContin patent dispute that required Endo to stop selling a generic version at the end of the year. In return, Purdue released the company from liability for any infringement of three Purdue patents.


Post a Comment

<< Home